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ABSTRACT
Background Myeloid inhibitory C-type lectin-like
receptor (MICL, Clec12A) is a C-type lectin receptor
(CLR) expressed predominantly by myeloid cells. Previous
studies have suggested that MICL is involved in
controlling inflammation.
Objective To determine the role of this CLR in
inflammatory pathology using Clec12A−/− mice.
Methods Clec12A−/− mice were generated
commercially and primarily characterised using the
collagen antibody-induced arthritis (CAIA) model.
Mechanisms and progress of disease were characterised
by clinical scoring, histology, flow cytometry, irradiation
bone-marrow chimera generation, administration of
blocking antibodies and in vivo imaging. Characterisation
of MICL in patients with rheumatoid arthritis (RA) was
determined by immunohistochemistry and single
nucleotide polymorphism analysis. Anti-MICL antibodies
were detected in patient serum by ELISA and dot-blot
analysis.
Results MICL-deficient animals did not present with
pan-immune dysfunction, but exhibited markedly
exacerbated inflammation during CAIA, owing to the
inappropriate activation of myeloid cells. Polymorphisms
of MICL were not associated with disease in patients
with RA, but this CLR was the target of autoantibodies
in a subset of patients with RA. In wild-type mice the
administration of such antibodies recapitulated the
Clec12A−/− phenotype.
Conclusions MICL plays an essential role in regulating
inflammation during arthritis and is an autoantigen in a
subset of patients with RA. These data suggest an
entirely new mechanism underlying RA pathogenesis,
whereby the threshold of myeloid cell activation can be
modulated by autoantibodies that bind to cell
membrane-expressed inhibitory receptors.
INTRODUCTION
The natural killer gene complex (NKC) encodes a
multitude of activating and inhibitory C-type lectin
receptors (CLRs), many of which play important
roles in the maintenance of immune homoeostasis.1
Loss or mutations in inhibitory CLRs, in particular,
are often associated with unchecked inflammation
and destructive autoimmunity.2 Notably, the NKC
has been associated with rheumatoid arthritis
(RA),3 4 but to date only one receptor within this
cluster, dendritic cell immunoreceptor (DCIR), has
been linked to this disease in humans.3 5
Myeloid inhibitory C-type lectin-like receptor
(MICL) (also known as DCAL-2, CLL-1 or KLRL1)
is an inhibitory receptor found in the ‘Dectin-1
cluster’ within the NKC, whose physiological func-
tion is unknown. MICL is highly expressed on
myeloid cells, particularly neutrophils, monocytes
and macrophages.6 It possesses a single extracellular
C-type lectin-like domain, that recognises endogen-
ous ligand(s),7 8 and a cytoplasmic tail containing
an immunoreceptor tyrosine-based inhibitory motif
that can transduce intracellular inhibitory signals.8 9
MICL-mediated intracellular signalling can modu-
late several cellular responses,8–11 and expression
levels of this receptor are substantially altered
during cellular activation,6 7 11 suggesting that it
has an immune regulatory role. Recent evidence
suggests that MICL can regulate inflammation in
response to cell death.8
There is also evidence implicating MICL in the
pathogenesis of RA. We have previously described a
potential link of polymorphisms in this receptor
with RA pathogenesis.12 Moreover, expression of
this receptor was shown to correlate with levels of
rheumatoid factor (RF) in patients with RA.13 Here
we have explored the physiological function of
MICL and its role in RA.
METHODS
MICL knockout mouse generation and cellular
characterisation
MICL knockout mice (Clec12A−/−) on a C57BL/6
background were produced by Taconic Artemis,
USA (see online supplementary figure S1A).
Clec12A−/− and wild-type (wt) mice were bred and
maintained at the Medical Research Facility,
University of Aberdeen. Mice were separately
housed in groups and provided freely with food
and water. All experimentation conformed to the
terms and conditions of UK Home Office licences
for research on animals (PPL 60/4007) and the
University of Aberdeen ethical review committee.
Characterisation of MICL expression in
8–12-week-old wt and Clec12A−/− mice was per-
formed by flow cytometry on cells isolated from
the peripheral blood, bone marrow, peritoneal
cavity, spleen and lungs, as previously described.14
Antibodies used in these experiments included
biotin anti-MICL monoclonal antibody 3097
and isotype control, as well as biotin-Gr-1,
FITC-7/4, PE-F480, biotin-F480, PerCpCy5.5-
CD11b, PE-CCR3, biotin-NK1.1, PE-CD49,
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PerCpCy5.5-B220, PE-CD19, PerCpCy5.5-CD3, biotin-CD4,
FITC-CD8, biotin-CD11c, PerCpCy5.5-Gr-1, APC-Ly6G,
PE-CD11b, PE-Ly6G, PECy7-CD11b, Alexa Fluor 488
anti-STAT5, APC-streptavidin (all from BD Biosciences), and
Alexa Fluor 700-F4/80 (BioLegend). Flow cytometry was under-
taken using a BD LSRFortessa cell analyser and data analysed
using FlowJo.
Models of inflammation and infection
Mice were injected intraperitoneally (IP) with 1.0 mL Brewer’s
thioglycollate broth (BD Biosciences) or challenged intratrache-
ally with either 100 ng lipopolysaccharide (LPS) or 1×107
highly purified β1,3-glucan particles.15 Cellular inflammation
was analysed by flow cytometry 24 h later, unless otherwise
indicated. To characterise resistance to systemic infection, mice
were injected intravenously (IV) with Candida albicans SC5314,
and fungal burdens and survival determined as described previ-
ously.16 The role of MICL in adaptive immunity was explored
by adoptively transferring 3×106 carboxyfluoresceinsuccinimi-
dyl ester-labelled CD45.1+ CD4+ OT.II cells into gender-
matched recipient mice, which were subsequently immunised
with 50 mg ovalbumin (Hyglos GmBH) in complete Freund’s
adjuvant (Difco). OT.II T cell responses were characterised at
day 4 after immunisation by flow cytometry.
Collagen antibody-induced arthritis
Mice were injected IV with 4 mg of ArthritoMab monoclonal
antibody cocktail (MD Biosciences), and then IP 3 days later
with 100 μg LPS (MD Biosciences). In some experiments,
0.7 mg of anti-MICL or isotype control antibodies were admi-
nistered IP every 24 h from day 4 to day 13. Daily clinical
scoring was undertaken using a scale of 0 (no visible signs of
redness or swelling) to 4 (extensive swelling with signs of
deformity). To generate radiation chimeras, animals received
2×500 rad (IBL437C irradiator, Cis Bio International) and
were then reconstituted with 2–4×106 bone marrow cells from
donor mice. For histology, joints were isolated, fixed, decalci-
fied, sectioned and stained with H&E. In vivo imaging was per-
formed using a Bruker in vivo MS FX Pro imager, after a single
IV administration of OsteoSense 680EX (NEV10020EX,
PerkinElmer, UK), 24 h before the start of the collagen
antibody-induced arthritis (CAIA) protocol. Twenty-four hours
before image acquisition, animals were also injected IV with
ProSense 750EX (NEV10001EX, PerkinElmer, UK).
Human samples
Immunohistochemistry was performed on synovial tissue sec-
tions from patients with RA using CD163 (AbD Serotec), anti-
human MICL (anti-hMICL) HB36 or an IgG1 isotype control
Figure 1 Myeloid inhibitory C-type lectin-like receptor (MICL) deficiency does not result in pan-immune dysfunction. (A) Flow cytometry analysis of
MICL expression in the bone marrow of wild-type (wt) and mClec12A−/− mice, as indicated. Time course analysis of (B) MICL expression and (C)
cellular composition in the peritoneal cavity after thioglycollate administration. Data are pooled from at least two independent experiments and in
(C) are the mean±SEM (n≥10). (D) Pulmonary neutrophil recruitment 24 h after the administration of LPS or glucan particles, as indicated. Data are
pooled from two independent experiments (n=8) and expressed as mean±SEM. (E) Loss of MICL does not affect survival or kidney fungal burdens
during systemic infection with Candida albicans (n≥10). (F) Loss of MICL does not affect the development of adaptive immunity. Characterisation of
the number, division and activation of adoptively transferred OT.II T-cells in the draining (d) and non-draining (nd) lymph nodes of wild-type (wt)
and Clec12A−/− animals, 4 days after immunisation with ovalbumin and complete Freund’s adjuvant. Shown are pooled data from at least two
independent experiments (n>10). CFU, colony-forming units; CFSE, carboxyfluoresceinsuccinimidyl ester; ko, knockout; ns, not significant; LPS,
lipopolysaccharide; MFI, mean fluorescence intensity; PMN, polymorphonuclear leukocyte; SSC, side scatter.
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(Sigma, Oakville, Ontario, Canada). Western blotting of syno-
viocyte cell suspensions with anti-MICL HB3 and horseradish
peroxidase-conjugated sheep anti-mouse IgG was performed
using standard methodology. Anti-hMICL was detected in
serum samples of controls and patients with RA by ELISA, using
immobilised highly purified recombinant Fc-hMICL (see online
supplementary figure S2A)6 or Fc-Dectin-1.17 Bound antibodies
were detected using horseradish peroxidase-conjugated goat
anti-human IgG F(ab0)2 fragment ( Jackson ImmunoResearch).
Specificity of this assay could be demonstrated by inhibition of
serum antibody binding with the addition of soluble Fc-MICL
(see online supplementary figure S2B). For dot blots, serum
samples were used to probe recombinant histidine-tagged
hMICL or histidine-tagged human C-type lectin superfamily
member 8 (ClecSF8; Creative Biomart), immobilised on nitro-
cellulose membranes and then detected with peroxidase-
conjugated goat anti-human IgG F(ab0)2 fragment ( Jackson
ImmunoResearch) or mouse anti-His monoclonal antibody
(Qiagen).
Serum samples from patients with RA (see online supplemen-
tary table S3) were obtained with consent from the Institute of
Infection, Immunity and Inflammation Research Tissue Bank,
Gartnavel General Hospital, Glasgow, UK and with ethical
approval from the West of Scotland research ethics service.
Serum samples were also obtained from consenting healthy
donors with the approval of the College of Life Sciences and
Medicine ethics review board, University of Aberdeen.
Statistical analysis
Two group analyses were performed using Student t tests,
whereas one-way analysis of variance with Bonferroni’s multiple
comparison test was used for multiple comparisons. Survival
was assessed by the log-rank test. All statistical analyses were
performed with GraphPad Prism software V.5.04.
RESULTS
MICL deficiency does not result in pan-immune regulatory
dysfunction
To explore a possible immune regulatory role for MICL, we
generated Clec12A−/− mice using conventional gene targeting,
and confirmed the deletion of exons 1–4 of the gene encoding
this receptor (Clec12A), corresponding to the cytoplasmic tail,
transmembrane, stalk and part of the C-type lectin domain, by
Southern blot and PCR analyses (see online supplementary
figure S1 and data not shown). Flow cytometry of cells
and tissues confirmed that MICL expression was abrogated
(figure 1A and see online supplementary figure S3). The MICL-
knockout mice were viable and had normal bone marrow (see
online supplementary table S1) and peripheral blood leucocyte
counts (see online supplementary table S2). Notably, unlike
other inhibitory CLRs, including DCIR,18 Clec12A−/− mice did
not exhibit any gross abnormalities during the first 12 months
of life (data not shown), suggesting that loss of MICL does not
result in the spontaneous development of autoimmunity.
To evaluate immune regulatory functionality, we first explored
the effect of MICL deficiency in a model of sterile peritonitis
induced by thioglycollate. After in vivo challenge, peritoneal
expression of MICL on leucocyte subsets reached a peak at 4 h
and then slowly decreased over time (figure 1B).
Characterisation of the composition of the cellular infiltrates in
the Clec12A−/− mice at several time points did not, however,
reveal any defects in inflammation (figure 1C). Moreover,
MICL deficiency had no effect on peritoneal inflammation
induced by several other stimuli (see online supplementary
figure S4). In addition, the knockout mice did not exhibit any
abnormalities in pulmonary inflammation induced by various
agonists (figure 1D and see online supplementary figure S4), or
resistance to systemic infection, using a fungal infection model
(figure 1E). Although MICL has been shown to regulate den-
dritic cell function and influence the development of adaptive
immunity,10 19 we did not detect any differences in the number,
division or activation of antigen-specific CD4+ T cells in the
draining lymph nodes of immunised Clec12A−/− mice
(figure 1F). Consistent with previous reports using another
knockout mouse line,8 we concluded that Clec12A−/− mice do
not exhibit pan-immune regulatory dysfunction.
MICL is required to control inflammation in murine models
of collagen antibody-induced arthritis
We next examined the effects of MICL deficiency during CAIA.
This model was chosen as it induces an inflammatory polyarthri-
tis reminiscent of the human disease and works efficiently on
Figure 2 Exacerbation of collagen
antibody-induced arthritis (CAIA) in
Clec12A−/− mice. (A) Severity scores
over time during CAIA. Shown are the
mean±SEM of pooled data from six
independent experiments (n>42).
*p<0.05. (B) Representative
histopathology of the ankle joints at
day 10 after immunisation. (C) In vivo
imaging and measurement of
inflammation during CAIA at day 17
after immunisation with ProSense
(n=6). MICL, myeloid inhibitory C-type
lectin-like receptor; wt, wild-type.
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the C57BL/6 background.20 In contrast to our results described
above, we elicited substantial regulatory deficit during CAIA in
Clec12A−/− mice (figure 2A). The peak of disease occurred
around day 7 in wt mice and subsequently resolved around day
13. In the Clec12A−/− mice disease severity was enhanced, with
a delayed zenith response (till day 11) and failed to resolve such
that, by day 20, animals still exhibited considerable articular
inflammation (figure 2A). Histological analysis showed mixed
leucocytic inflammatory infiltrates and signs of periarticular
bone erosion in the joints of the knockout mice (figure 2B). In
vivo imaging revealed increased bone remodelling (see online
supplementary figure S5) and inflammation (figure 2C) in the
MICL-deficient animals. Together, these data suggest that MICL
plays a fundamental role in controlling the pathology of CAIA.
To gain mechanistic insight, we characterised the peripheral
blood of wild-type and MICL-deficient mice during CAIA. We
observed a significant reduction in Gr-1hiCD11bhi neutrophils
in the Clec12A−/− mice, consistent with the increased inflamma-
tion seen in these animals (figure 3A and online supplementary
figure S6). In line with the loss of an inhibitory receptor,9
MICL-deficient cells expressed increased phosphorylated
STAT-5 during CAIA (figure 3B), indicating enhanced myeloid
cell activation,9 a phenotype similar to that seen in mice lacking
the related receptor, DCIR.18
To confirm that the phenotype of the Clec12A−/− mice
stemmed from the myeloid compartment, we generated
irradiation-derived bone marrow chimeric mice (figure 3C and
see online supplementary figure S7). Reconstitution of wild-type
or Clec12A−/− mice with MICL-knockout bone marrow exacer-
bated CAIA and prevented resolution of the disease, as before
(figure 3C, right panels). In contrast, there was a reversion to
normal progression and resolution of CAIA in Clec12A−/−
animals that had received wild-type bone marrow (figure 3C,
left panels). These data demonstrate that the phenotype of
Clec12A−/− mice during CAIA stems from inappropriate regula-
tion of myeloid cells.
MICL is an autoantigen in a subset of patients with RA
To translate the relevance of these observations to human
disease, we first examined the expression of hMICL in the syno-
vium of patients with RA and controls, using monoclonal anti-
bodies which are specific for human MICL.6
Immunohistochemical analysis disclosed the presence of hMICL
in the synovial lining layer and in scattered subsynovial cells of
patients with RA, but that there was little or no expression in
non-inflamed synovium (figure 4A). Western blotting of RA syn-
ovial cell lysates further confirmed expression of the various gly-
coforms of MICL6 (see online supplementary figure S8).
Staining of serial sections with CD163 suggested that MICL was
expressed on cells of the macrophage/monocytic linage in
inflamed synovial tissue (figure 4B).
The gene cluster in which MICL is located has been linked
with RA,3 5 and we recently reported that polymorphisms of
hMICL could potentially be associated with this disease.12 We
reassessed the contribution of this gene within the much larger
cohort of the Wellcome Trust Case Control Consortium.21
Figure 3 Exacerbated collagen
antibody-induced arthritis (CAIA) in
Clec12A−/− mice stems from
inappropriate myeloid cell activation.
(A) Percentage of Gr-1hiCD11bhi
neutrophils and (B) expression of
phosphorylated Stat-5 (pY694) at day
10 after immunisation. Data are shown
as mean±SD. (C) Development of CAIA
in reconstituted irradiated bone
marrow chimeras, as indicated (ko,
knockout; wt, wild-type). Shown are
mean±SEM of pooled data from four
independent experiments (n=8–24).
*p<0.05. MICL, myeloid inhibitory
C-type lectin-like receptor.
Figure 4 Myeloid inhibitory C-type lectin-like receptor (MICL) is
expressed on myeloid cells during human rheumatoid arthritis (RA).
(A) Immunohistochemical analysis of expression of hMICL (brown) in
haematoxylin-stained synovial tissue sections from three patients with
RA (top panels) and non-inflamed synovium from a patient with
osteoarthritis (bottom panels). (B) Immunohistochemical analysis of
serial sections of RA synovium probed for CD163 or αhMICL, as
indicated. Sections were counterstained with haematoxylin. Scale bar,
50 μm.
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However, there was no genome-wide significant association of
any polymorphism in and around Clec12A with RA (figure 5).
Expression of hMICL has also been correlated with raised
levels of RF,13 so we next explored the possibility that hMICL
was a target of autoantibodies in patients with RA. Notably, we
could demonstrate serum reactivity to hMICL in more than
60% of patients with RA tested by ELISA, and no reactivity in
healthy controls (figure 6A). These serum samples were selected
at random from a small cohort of RF-positive and
anti-citrullinated protein antibody (APCA)-positive patients with
RA (see online supplementary table S3). To confirm this obser-
vation by an alternative method, we also directly demonstrated
this serum reactivity by dot-blot analysis under native conditions
(figure 6B). Serum reactivity was abolished under non-native
conditions (see online supplementary figure S9). We did not
detect any correlation between serum antibody levels and
C-reactive protein levels or 28-joint count Disease Activity
Scores in these patients (see online supplementary figure S10).
Thus, these data demonstrate that a subset of patients with RA
develop autoantibodies to MICL.
To determine whether anti-MICL antibodies could function-
ally influence the progression of arthritis, we turned to our
animal models. For these experiments, we administered
anti-mMICL monoclonal antibodies IP every 24 h from day 4 to
day 13, after induction of CAIA in wild-type mice. We have pre-
viously described these antibodies and shown that they are spe-
cific for murine MICL.7 Remarkably, administration of these
monoclonal antibodies increased the severity of the disease and
prolonged its duration, reminiscent of the phenotype seen in
the Clec12A−/− mice (figure 6C). Thus these results demonstrate
that antibodies to MICL can exacerbate arthritic inflammation.
DISCUSSION
Myeloid cells are considered central to RA pathogenesis.22 In
this study we show that MICL can directly regulate the activa-
tion of myeloid lineage cells in inflammatory articular responses.
The increased pSTAT-5 levels seen in the Clec12A knockout
mice, and the previously demonstrated ability of MICL to
control cellular responses,8 9 indicate that the inhibitory signal-
ling induced by this receptor is essential to control inflammation
during CAIA. These functions of MICL are probably triggered
following the recognition of cell death,8 which occurs in the
synovium during active inflammation.22
Although MICL is not genetically associated with RA in
humans (Okada et al23 and this study), we have discovered that
this receptor is the target of autoantibodies in a subset of these
patients. Although our cohort size was small, the production of
autoantibodies, particularly ACPA, is a key feature in RA, and
they serve as important diagnostic and prognostic indicators.22
Recently, direct functional activities mediated by ACPA—for
example, via FcR dependent pathways, and osteoclast
Figure 5 Association between single nucleotide polymorphisms
(SNPs) near Clec12A and rheumatoid arthritis (RA) in the Wellcome
Trust Case Control Consortium (WTCC). Tests of genetic association
with RA were performed as part of the WTCC.21 For SNPs in and
around the Clec12A locus, the −log10 (p value) from each association
test is plotted against SNP chromosomal location (red dot). The purple
diamond indicates rs536957 (p=0.81; OR=0.99 (95% CI 0.88 to 1.10)),
which is perfectly correlated in this dataset with rs1323461, the
Clec12A variant previously associated with RA.12 Recombination rates
across the region are given by the blue line; and RefSeq gene locations
are indicated by green arrows. No variants in this region achieved
genome-wide significance.
Figure 6 Myeloid inhibitory C-type
lectin-like receptor (MICL) is an
autoantigen in human rheumatoid
arthritis (RA). (A) ELISA-based analyses
of anti-hMICL reactivity in serum
samples from patients with RA and
healthy donors. (B) Dot-blot analysis of
reactivity to his-tagged MICL (hMICL)
and control proteins in two patients
with RA and a normal control.
(C) Exacerbation of collagen
antibody-induced arthritis in wild-type
mice after the intraperitoneal
administration of anti-mMICL and
isotype control monoclonal antibodies,
as described in ‘Methods’. Shown are
pooled data from two independent
experiments (n=10). *p<0.05.
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maturation via citrullinated-vimentin recognition have attracted
increasing attention.24 Importantly, we now demonstrate that
anti-MICL antibodies can exacerbate disease, at least in murine
models, suggesting a new means whereby resolution can fail and
myeloid-dependent inflammation can prevail.
There is increasing realisation that failed resolution is pivotal
in driving the evolution of RA from undifferentiated inflamma-
tory arthritis. Given the central role of myeloid lineage cells in
synovitis most attention has focused on activation pathways,
including TLR, FcR, NLR, PAR2 and T cell-driven lectin-
dependent interactions.22 That a deficient autoregulatory
pathway may also contribute has thus far not been identified.
We thus offer an entirely new mechanism underlying disease
perpetuation, or failed resolution, in which the ‘threshold’ for
myeloid cell activation is modulated by autoantibody to regula-
tory cell-surface receptors, directly influencing the severity and
persistence of inflammatory synovitis. Although further work is
required to confirm that these autoantibodies have functional
effects, our observations have implications for the diagnosis,
stratification and treatment of this disease in patients.
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